Vivani Medical, Inc. VANI and Okava Prescribed drugs, Inc. expanded their collaboration to incorporate canines within the improvement of OKV-119, a long-acting GLP-1 remedy for weight administration, diabetes and different cardiometabolic circumstances.
Monetary phrases of the expanded settlement weren’t disclosed.
Okava Prescribed drugs is a clinical-stage firm centered on ailments of ageing in canines and cats.
Vivani and Okava initiated their collaboration in 2019, specializing in creating OKV-119 for cardiometabolic circumstances in cats.
Additionally Learn: EXCLUSIVE: Vivani Medical To Spin Off Cortigent Neurostimulation Enterprise To Create Higher Focus On Particular person Entities And Shareholder Worth
OKV-119 leverages Vivani’s proprietary NanoPortal expertise, which gives easy and regular supply of therapeutic molecules, together with GLP-1 receptor agonists, over prolonged durations from a single implant.
In response to Okava, dosing each six months or longer helps a “One-and-Performed” method between workplace visits in line with the product profile of Vivani’s NPM-115, an extremely long-acting GLP-1 implant in medical stage improvement to enhance remedy adherence and tolerability for the remedy of continual weight administration in people.
“This expanded partnership with Okava displays our shared confidence within the potential of NanoPortal expertise to serve a broad array of potential beneficiaries within the administration of metabolic illness. The construction of this expanded partnership minimizes prices and dangers for Vivani whereas integrating upside potential for Vivani shareholders via future milestone funds and royalties,” stated Vivani CEO Adam Mendelsohn.
In March, Vivani Medical launched preclinical information for NPM-139, its subdermal semaglutide implant beneath improvement for continual weight administration in overweight and chubby people.
In an ongoing examine in wholesome rats, a single administration of the semaglutide implant NPM-139 resulted in physique weights almost 20% decrease than a sham implant management group all through a 91-day remedy interval.
Worth Motion: VANI inventory closed at $1.04 on Monday.
Learn Subsequent:
Market Information and Knowledge delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
